Trial Profile

A registrational study of MDNA11 for 2L/3L melanoma and select other tumor types post-ICI failure

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MDNA 11 (Primary)
Indications Malignant melanoma; Solid tumours
Focus Therapeutic Use

Most Recent Events

03 Feb 2026 New trial record
15 Jan 2026 According to a Medicenna Therapeutics media release, the company expects to secure FDA guidance on first potential registrational trial of MDNA11 in at least one advancer cancer indication in 2L/3L setting post-ICI therapy, including dose selection for Project Optimus in 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com